PARP1 and cancer: While PARP1/2 inhibitors are widely used as a cancer therapy in the clinic (Bhamidipati et al., 2023), focus is shifting to the development of inhibitors for other PARPs are therapies for cancer and other diseases (Kirby et al., 2018; Falchook et al., 2021; Schenkel et al., 2021; Eddie et al., 2022; Niepel et al., 2022; Yap et al., 2023; Wong et al., 2023).